Historical review of melanoma treatment and outcomes.

[1]  J. Kirkwood,et al.  Prognostic significance of autoimmunity during treatment of melanoma with interferon , 2006, Seminars in Immunopathology.

[2]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[3]  A. Hauschild,et al.  Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Kirkwood,et al.  Immunogenicity and Antitumor Effects of Vaccination with Peptide Vaccine +/− Granulocyte-Monocyte Colony-Stimulating Factor and/or IFN-α2b in Advanced Metastatic Melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696 , 2009, Clinical Cancer Research.

[5]  E. Simpson,et al.  Frequent somatic mutations of GNAQ in uveal melanoma and blue nevi , 2008, Nature.

[6]  H. Pehamberger,et al.  Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[8]  D. Pinkel,et al.  Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Jeffrey E. Lee,et al.  Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma , 1998, Annals of Surgical Oncology.

[10]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[11]  J. Kirkwood,et al.  Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? , 2004, European journal of cancer.

[12]  K. Søndergaard,et al.  Therapeutic and clinico-pathological factors in the survival of 1,469 patients with primary cutaneous malignant melanoma in clinical stage I , 1985, Virchows Archiv A.

[13]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[14]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[15]  J. Kirkwood,et al.  Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  N Cascinelli,et al.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  N. Cascinelli,et al.  Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial , 1998, The Lancet.

[19]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Mihm,et al.  Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. , 1996, Annals of surgery.

[21]  R. Henderson,et al.  Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.

[22]  S. Rosenberg,et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Coulie,et al.  The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1993, The Journal of experimental medicine.

[24]  M. Mihm,et al.  Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. , 1993, Annals of surgery.

[25]  Max H. Myers,et al.  Manual for Staging of Cancer , 1992 .

[26]  D L Morton,et al.  Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.

[27]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[28]  D. Morton,et al.  Lymphatic drainage of skin to a sentinel lymph node in a feline model. , 1991, Annals of surgery.

[29]  C. Balch,et al.  Thin Stage I Primary Cutaneous Malignant Melanoma , 1988 .

[30]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[31]  J. Kirkwood,et al.  Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. , 1985, Annals of internal medicine.

[32]  J. Manning,et al.  Alpha interferon for induction of remission in hairy-cell leukemia. , 1984, The New England journal of medicine.

[33]  Mcbride Cm,et al.  Excision of underlying fascia with a primary malignant melanoma: effect on recurrence and survival rates. , 1982 .

[34]  N. Cascinelli,et al.  Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities , 1982, Cancer.

[35]  S. Rosenberg,et al.  Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins. , 1982, Cancer research.

[36]  S. Rosenberg,et al.  Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. , 1981, Cancer research.

[37]  T. Taniguchi,et al.  Construction and identification of a bacterial plasmid containing the human fibroblast interferon gene sequence. , 1979 .

[38]  K. Cantell,et al.  Large scale production and properties of human leukocyte interferon used in clinical trials. , 1978, Advances in experimental medicine and biology.

[39]  N. Cascinelli,et al.  Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. , 1977, The New England journal of medicine.

[40]  M. Hanna,et al.  Regression of established intradermal tumors and lymph node metastases in guinea pigs after systemic transfer of immune lymphoid cells. , 1977, Journal of the National Cancer Institute.

[41]  D. Morton,et al.  Regional lymphatic drainage in primary malignant melanoma of the trunk determined by colloidal gold scanning. , 1977, Surgical forum.

[42]  R. Gallo,et al.  Selective in vitro growth of T lymphocytes from normal human bone marrows. , 1976, Science.

[43]  T. Foley,et al.  NEONATAL SCREENING FOR HYPOTHYROIDISM , 1975, The Lancet.

[44]  S. Waltman,et al.  Glaucoma and HL-A antigens , 1975, The Lancet.

[45]  D. Morton,et al.  Sensitisation of lymphocytes in vitro against human melanoma-associated antigens , 1974, Nature.

[46]  R. Ruess,et al.  Chemotherapy of Malignant Melanoma with Dimethyl Triazeno lmidazole Carboxamide (DITC) and Nitrosourea Derivatives (BCN U, CCNU) , 1974, Annals of surgery.

[47]  R. F. Ryan,et al.  Chemotherapy of Melanoma of the Extremities by Perfusion: Fourteen Years Clinical Experience , 1972, Annals of surgery.

[48]  G. Ramírez,et al.  Combination phase 1-II study of imidazole carboxamide (NCS45388). , 1972, Oncology.

[49]  J. Wolter,et al.  Characteristics of prognosis and response to an imidazole carboxamide in malignant melanoma , 1971, Clinical pharmacology and therapeutics.

[50]  A Breslow,et al.  Thickness, Cross‐Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous Melanoma , 1970, Annals of surgery.

[51]  D. Morton,et al.  Immunological Factors in Human Sarcomas and Melanomas: A Rational Basis for Immunotherapy , 1970, Annals of surgery.

[52]  D. Morton,et al.  Immunological factors which influence response to immunotherapy in malignant melanoma. , 1970, Surgery.

[53]  R. Livingston,et al.  Single Agents in Cancer Chemotherapy , 1970, Springer US.

[54]  I. Gresser,et al.  Exogenous Interferon and Inducers of Interferon in the Treatment of Balb/c Mice inoculated with RC19 Tumour Cells , 1969, Nature.

[55]  W. Clark,et al.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin. , 1969, Cancer research.

[56]  D. Morton,et al.  Demonstration of antibodies against human malignant melanoma by immunofluorescence. , 1968, Surgery.

[57]  A. G. Foraker,et al.  Spontaneous regression of human melanoma. Clinical and experimental studies , 1960, Cancer.

[58]  Everson Tc,et al.  Spontaneous regression of cancer. , 1967, Progress in clinical cancer.

[59]  J. Lindenmann,et al.  Virus interference. I. The interferon , 1957, Proceedings of the Royal Society of London. Series B - Biological Sciences.

[60]  R. Valentine,et al.  Virus interference. II. Some properties of interferon , 1957, Proceedings of the Royal Society of London. Series B - Biological Sciences.

[61]  P. Medawar,et al.  Quantitative Studies on Tissue Transplantation Immunity. III. Actively Acquired Tolerance , 1956, Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences.

[62]  W. Norris.  Case of Fungoid Disease , 1820, Edinburgh medical and surgical journal.